Hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) breast cancer is the most common breast cancer subtype,6, 7, 8 with endocrine therapy (ET) playing a central role as the therapeutic backbone.9 This evidence concerns the gene ERBB2 and breast carcinoma.